NCT06295809 — intismeran autogene (mRNA-4157) neoantigen vaccine trial
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Registry record
| Registry ID | NCT06295809 ↗ |
|---|---|
| Lead sponsor | Merck Sharp & Dohme LLC |
| Collaborators | ModernaTX, Inc. |
| Phase | Phase 2/3 |
| Status | Terminated |
| Indication | Carcinoma, Squamous Cell, Skin Neoplasms |
| Enrollment | 46 participants (target) |
| Start date | 2024-04-18 |
| Primary completion | 2026-03-05 |
| Last registry update | 8 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06295809), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06295809?
NCT06295809 (A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)) is registered on ClinicalTrials.gov as Phase 2/3, sponsored by Merck Sharp & Dohme LLC.
Is NCT06295809 recruiting?
As of the 2026-05-08 registry update, NCT06295809 is listed as "Terminated". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06295809?
The lead sponsor is Merck Sharp & Dohme LLC. Collaborators: ModernaTX, Inc..
What condition does NCT06295809 study?
The registered conditions are Carcinoma, Squamous Cell, Skin Neoplasms. Primary completion is listed as 2026-03-05.
Are results available for NCT06295809?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06295809.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.